Affimed is a clinical-stage immuno-oncology company focused on discovering and developing targeted cancer immunotherapies. Co.'s main candidate, AFM13, is an innate cell engager (ICE®) designed for the treatment of certain CD30-positive malignancies, including for both Hodgkin lymphoma and certain non-Hodgkin lymphomas. Co.'s second candidate, AFM24, is designed to address limitations, such as toxicities or treatment resistance, associated with existing therapeutic anti-epidermal growth factor receptor monoclonal antibodies. Co.'s third wholly-owned ICE® molecule, AFM28, was developed from its ROCK® platform and is designed to bind to CD123, an established target in myeloid malignancies. The AFMD stock yearly return is shown above.
The yearly return on the AFMD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AFMD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|